SELLAS Life Sciences (SLS) Total Current Liabilities (2010 - 2026)

SELLAS Life Sciences (SLS) reported Total Current Liabilities of $6.5 million for Q1 2026, down 6.27% year-over-year from $6.9 million in Q1 2025, and down 7.99% on a QoQ basis from $7.0 million in Q4 2025.

SELLAS Life Sciences (SLS) has 17 years of Total Current Liabilities data on file, last reported at $6.5 million in Q1 2026.

  • Quarterly Total Current Liabilities fell 6.27% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 6.27% YoY) and the FY2025 annual result came in at $7.0 million, down 26.21% from the prior year.
  • Total Current Liabilities slipped to $6.5 million in Q1 2026 per SLS's latest filing, from $7.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $15.5 million in Q4 2022 and bottomed at $5.9 million in Q3 2025.
  • The 5-year median for Total Current Liabilities is $11.7 million (2023), against an average of $10.8 million.
  • The widest annual swing landed in 2022, when Total Current Liabilities jumped 211.42%; it then slumped 52.29% in 2025.
  • Tracing SLS's Total Current Liabilities over 5 years: stood at $15.5 million in 2022, then dropped by 11.47% to $13.7 million in 2023, then sank by 30.76% to $9.5 million in 2024, then slipped by 26.21% to $7.0 million in 2025, then declined by 7.99% to $6.5 million in 2026.
  • Per Business Quant, the three latest SLS Total Current Liabilities figures stand at $6.5 million (Q1 2026), $7.0 million (Q4 2025), and $5.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 16.35 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 1.70 Mn
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 636.40 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 66.94 Mn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 13.42 Mn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 3.88 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 5.11 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.35 Bn
10 SELLAS Life Sciences 1.61 Bn 1.61 Bn - 6.46 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 6.46 Mn
Dec 31, 2025 7.02 Mn
Sep 30, 2025 5.93 Mn
Jun 30, 2025 6.00 Mn
Mar 31, 2025 6.89 Mn
Dec 31, 2024 9.51 Mn
Sep 30, 2024 10.61 Mn
Jun 30, 2024 12.05 Mn
Mar 31, 2024 14.44 Mn
Dec 31, 2023 13.74 Mn
Sep 30, 2023 11.74 Mn
Jun 30, 2023 13.42 Mn
Mar 31, 2023 15.51 Mn
Dec 31, 2022 15.52 Mn
Sep 30, 2022 12.55 Mn
Jun 30, 2022 12.19 Mn
Mar 31, 2022 10.68 Mn
Dec 31, 2021 4.98 Mn
Sep 30, 2021 5.32 Mn
Jun 30, 2021 4.24 Mn
Mar 31, 2021 5.97 Mn
Dec 31, 2020 12.34 Mn
Sep 30, 2020 4.22 Mn
Jun 30, 2020 4.33 Mn
Mar 31, 2020 3.64 Mn
Dec 31, 2019 5.29 Mn
Sep 30, 2019 5.57 Mn
Jun 30, 2019 5.40 Mn
Mar 31, 2019 5.80 Mn
Dec 31, 2018 5.97 Mn
Sep 30, 2018 12.00 Mn
Jun 30, 2018 24.85 Mn
Mar 31, 2018 25.75 Mn
Dec 31, 2017 24.57 Mn
Sep 30, 2017 28.02 Mn
Jun 30, 2017 34.54 Mn
Mar 31, 2017 36.27 Mn
Dec 31, 2016 5.76 Mn
Sep 30, 2016 42.54 Mn
Jun 30, 2016 47.22 Mn
Mar 31, 2016 42.22 Mn
Dec 31, 2015 57.07 Mn
Sep 30, 2015 37.09 Mn
Jun 30, 2015 38.11 Mn
Mar 31, 2015 33.96 Mn
Dec 31, 2014 27.23 Mn
Sep 30, 2014 31.59 Mn
Jun 30, 2014 33.41 Mn
Mar 31, 2014 26.84 Mn
Dec 31, 2013 62.47 Mn
Sep 30, 2013 36.51 Mn
Jun 30, 2013 25.75 Mn
Mar 31, 2013 26.38 Mn
Dec 31, 2012 15.92 Mn
Sep 30, 2012 10.06 Mn
Mar 31, 2012 27.39 Mn
Dec 31, 2011 11.20 Mn
Sep 30, 2011 21.46 Mn
Jun 30, 2011 19.55 Mn
Dec 31, 2010 5.03 Mn